Treatment availability and financial obstacles to adherence in bronchial asthma and COPD sufferers in low-resource settings
You can view the original post here
Soriano, J. B. et al. Prevalence and attributable well being burden of continual respiratory ailments, 1990-2017: a scientific evaluation for the International Burden of Illness Examine 2017. Lancet Respir. Med. 8, 585–596 (2020).
Beran, D., Zar, H. J., Perrin, C., Menezes, A. M. & Burney, P. Burden of bronchial asthma and continual obstructive pulmonary illness and entry to important medicines in low-income and middle-income nations. Lancet Respir. Med. 3, 159–170 (2015).
Brakema, E. A. et al. FRESH AIR collaborators. The socioeconomic burden of continual lung illness in low-resource settings throughout the globe - an observational FRESH AIR examine. Respir. Res. 20, 291 (2019).
Sullivan, P. W. et al. Measuring the price of poor bronchial asthma management and exacerbations. J. Bronchial asthma 54, 24–31 (2017).
Lee, L. Ok., Obi, E., Paknis, B., Kavati, A. & Chipps, B. Bronchial asthma management and illness burden in sufferers with bronchial asthma and allergic comorbidities. J. Bronchial asthma 55, 208–219 (2018).
Singh, D. et al. International Technique for the Prognosis, Administration, and Prevention of Continual Obstructive Lung Illness: the GOLD science committee report 2019. Eur. Respir. J. 53, 1900164 (2019).
Tabyshova, A. et al. Gaps in COPD Tips of Low- and Center-Earnings Nations: A Systematic Scoping Overview. Chest 159, 575–84 (2021).
WHO Mannequin Checklist of Important Medicines (twenty first record). https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf (2019).
Bazargani, Y. T., de Boer, A., Leufkens, H. G. M. & Mantel-Teeuwisse, A. Ok. Important medicines for COPD and bronchial asthma in low and middle-income nations. Thorax 69, 1149–51 (2014).
Bissell, Ok., Perrin, C. & Beran, D. Entry to important medicines to deal with continual respiratory illness in low-income nations. Int J. Tuberc. Lung Dis. 20, 717–728 (2016).
Babar, Z. U., Lessing, C., Mace, C. & Bissell, Ok. The supply, pricing and affordability of three important bronchial asthma medicines in 52 low- and middle-income nations. Pharmacoeconomics 31, 1063–1082 (2013).
Kibirige, D. et al. Entry to reasonably priced medicines and diagnostic checks for bronchial asthma and COPD in sub Saharan Africa: the Ugandan perspective. BMC Pulm. Med. 17, 179 (2017).
Usmani, O. S. et al. Essential inhaler errors in bronchial asthma and COPD: a scientific assessment of affect on well being outcomes. Respir. Res. 19, 10 (2018).
Mäkelä, M. J., Backer, V., Hedegaard, M. & Larsson, Ok. Adherence to inhaled therapies, well being outcomes and prices in sufferers with bronchial asthma and COPD. Respir. Med. 107, 1481–1490 (2013).
Laba, T. L. et al. Price-related underuse of medicines for asthma-opportunities for bettering adherence. J. Allergy Clin. Immunol. Pr. 7, 2298–2306 (2019).
Plaza, V. et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for bronchial asthma and COPD sufferers. J. Aerosol Med. Pulm. Drug Deliv. 29, 142–152 (2016).
World Well being Group. Adherence to long-term therapies: proof for motion. https://apps.who.int/iris/handle/10665/42682 (2003).
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. & Feinstein, A. R. A simulation examine of the variety of occasions per variable in logistic regression evaluation. J. Clin. Epidemiol. 49, 1373–1379 (1996).
Bursac, Z., Gauss, C. H., Williams, D. Ok. & Hosmer, D. W. Purposeful choice of variables in logistic regression. Supply Code Biol. Med. 3, 17 (2008).
Zurdinova, A. et al. Scientific justification of rational pharmacotherapy within the improvement and implementation of scientific pointers primarily based on the ideas of proof medication. Dissertation. UDC 615.084:001:616-071:616(02) (2018).
Tabyshova, A. et al. Medical traits, therapy patterns and financial burden of COPD in Kyrgyzstan: a FRESH AIR examine. Int. J. Chron. Impede. Pulmon. Dis. 16, 2833–2843 (2021).
Klijn, S. L. et al. Effectiveness and success elements of instructional inhaler approach interventions in bronchial asthma & COPD sufferers: a scientific assessment. NPJ Prim. Care Respir. Med. 27, 24 (2017).
Ahn, J. H. et al. The consequences of repeated inhaler gadget dealing with training in COPD sufferers: a potential cohort examine. Sci. Rep. 10, 19676 (2020).
Takemura, M. et al. Relationships between repeated instruction on inhalation remedy, medicine adherence, and well being standing in continual obstructive pulmonary illness. Int J. Chron. Impede. Pulmon. Dis. 6, 97–104 (2011).
Plaza, V. et al. Variations in adherence and non-adherence behaviour patterns to inhaler units between COPD and bronchial asthma sufferers. COPD: J. Continual Obstr. Pulm. Dis. 13, 547–554 (2016).
Vestbo, J. et al. Adherence to inhaled remedy, mortality and hospital admission in COPD. Thorax 64, 939–943 (2009).
Ágh, T., Inotai, A. & Mészáros, Á. Elements related to medicine adherence in sufferers with continual obstructive pulmonary illness. Respiration 82, 328–334 (2011).
Darbà, J., Ramírez, G., Sicras, A., Francoli, P. & Torvinen, S. Sánchez-de la Rosa, R. The significance of inhaler units: the selection of inhaler gadget could result in suboptimal adherence in COPD sufferers. Int J. Chron. Impede. Pulmon. Dis. 10, 2335–2345 (2015).
Elander, A. G. M. Inhaler approach and self-reported adherence to medicines amongst hospitalised folks with bronchial asthma and COPD. Medication Actual. World Outcomes 7, 317–23 (2020).
López-Campos, J. L., Quintana Gallego, E. & Carrasco Hernández, L. Standing of and techniques for bettering adherence to COPD therapy. Int. J. Chron. Impede. Pulmon. Dis. 14, 1503–15 (2019).
Corden, Z. M., Bosley, C. M., Rees, P. J. & Cochrane, G. M. Residence nebulized remedy for sufferers with COPD: affected person compliance with therapy and its relation to high quality of life. Chest 112, 1278–1282 (1997).
Krigsman, Ok., Moen, J., Nilsson, J. L. & Ring, L. Refill adherence by the aged for bronchial asthma/continual obstructive pulmonary illness medication allotted over a 10-year interval. J. Clin. Pharm. Ther. 32, 603–611 (2007).
Apter, A. J., Reisine, S. T., Affleck, G., Barrows, E. & ZuWallack, R. L. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief variations. Am. J. Respir. Crit. Care Med. 157, 1810–1817 (1998).
Duarte-de-Araújo, A., Teixeira, P., Hespanhol, V. & Correia-de-Sousa, J. COPD: understanding sufferers’ adherence to inhaled medicines. Int J. Chron. Impede. Pulmon. Dis. 13, 2767–73 (2018).
Claxton, A. J., Cramer, J. & Pierce, C. A scientific assessment of the associations between dose regimens and drugs compliance. Clin. Ther. 23, 1296–310 (2001).
van de Hei, S. J., Dierick, B. J. H., Aarts, J. E. P., Kocks, J. W. H. & van Boven, J. F. M. Customized medicine adherence administration in bronchial asthma and continual obstructive pulmonary illness: a assessment of efficient interventions and improvement of a sensible adherence toolkit. J. Allergy Clin. Immunol. Pract. 9, 3979–3994 (2021).
Jansen, E. M. et al. International burden of medicine non-adherence in continual obstructive pulmonary illness (COPD) and bronchial asthma: a story assessment of the scientific and financial case for sensible inhalers. J. Thorac. Dis. 13, 3846–3864 (2021).
You can view the original post here Show Original: https://librareview.com/treatment-availability-and-financial-obstacles-to-adherence-in-bronchial-asthma-and-copd-sufferers-in-low-resource-settings/
Comments
Post a Comment